Hot Investor Mandate: China Investment Firm Deploys Up to $5M in Early-Stage Companies & $50M in Growth-Stage Companies Across Various Life Science Sectors

18 Jun

An investment firm headquartered in China with an additional office in the USA invests exclusively in the life science sector; the firm invests primarily in the USA and China, but will also invest in other regions such as Europe and Canada. Within China, the firm makes growth investments in companies that have existing revenues; in the USA and other regions, the firm makes both venture and growth-equity stage investments in both pre-revenue and revenue-stage companies. The firm’s allocations are highly varied. From the main fund, investments typically range from $15-50 million, though larger investments are of interest as well; the firm has another fund focused on earlier stage companies that actively makes investments of typically $2-5 million, generally in financing rounds of $10 million or less. The firm is open to syndication. The firm is also particularly interested in working with companies that are open to or actively interested in seeking partnerships or opportunities in China.

The firm invests in therapeutics, medical devices, diagnostics, healthcare services, and clinically-oriented healthcare IT, and will consider investing in any indication area or technology subsector; however, orphan indications, dermatology/aesthetics, oncology, and blood diseases are of particular interest in the biopharma space; general surgery, neurovascular, cardiovascular, minimally invasive technologies, women’s health, respiratory care, novel diagnostics and orthopedics are of particular interest in the device space. The fund for earlier stage companies focuses on early stage opportunities in biotech; from the main fund, the firm in most cases makes investments in products that have obtained market approval or are very close to commercialization, but earlier investments may be considered for highly innovative products or products that can demonstrate strong efficacy signals at an earlier stage (such as anti-infectives). For devices and diagnostics, the firm only invests in commercial-stage companies.  Generally, the firm does not invest in imaging.

The firm is flexible regarding management teams, and works with both serial entrepreneurs and entrepreneurs who lack industry experience.  In addition to investing in private companies, the firm is able to invest in public companies by means of PIPEs or public market placements. The firm is interested in investing in companies with products that can demonstrate cost-effectiveness.

If you are interested in more information about this investor and other investors tracked by LSN, please email

Leave a Reply

Fill in your details below or click an icon to log in: Logo

You are commenting using your account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )

Connecting to %s

%d bloggers like this: